PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification [7] : C12N 15/12, 15/62, 15/85, 5/10, C07K 14/715, 14/71, C12Q 1/68	**A1**	(11) International Publication Number: **WO 00/06722** (43) International Publication Date: 10 February 2000 (10.02.00)

(21) International Application Number: PCT/EP99/05491

(22) International Filing Date: 27 July 1999 (27.07.99)

(30) Priority Data:
98202528.0   28 July 1998 (28.07.98)   EP

(71) Applicant (for all designated States except US): VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECH-NOLOGIE VZW [BE/BE]; Rijvisschestraat 120, B-9052 Zwijnaarde (BE).

(72) Inventors; and
(75) Inventors/Applicants (for US only): VAN OSTADE, Xaveer [BE/BE]; Kopkapelstraat 49, B-9160 Lokeren (BE). VANDEKERCKHOVE, Joël, Stefaan [BE/BE]; Rode Beukendreef 27, B-8210 Loppem (BE). VERHEE, Annick [BE/BE]; Pastoor Denyslaan 60, B-8810 Lichtervelde (BE). TAVERNIER, Jan [BE/BE]; Bottelweg 2, B-9860 Balegem (BE).

(74) Common Representative: VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW; Rijvisschestraat 120, B-9052 Zwijnaarde (BE).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

---

(54) Title: EUKARYOTIC CELL-BASED GENE INTERACTION CLONING

(57) Abstract

The present invention relates to a method for screening compounds for their ability to bind a receptor and/or the screening of compounds that antagonise the binding of a ligand to a receptor. It is the aim of the present invention to provide an easy and powerful screening method in eukaryotic cells, such as insect cells, plant cells or mammalian cells, with the exclusion of yeast cells, for ligands of orphan receptors, preferentially of the multimerizing receptor type, for unknown ligands of known receptors, preferentially multimerizing receptors and for the genes encoding these ligands.

EUKARYOTIC CELL-BASED GENE INTERACTION CLONING

5   The present invention relates to a method for screening compounds for their ability to bind a receptor and/or the screening of compounds that antagonise the binding of a ligand to a receptor.

Receptors are defined as proteinaceous macromolecules that are often located on cell membranes and that perform a signal transducing function.

10   Many receptors are located on the outer cell membrane. Several receptors possess three domains, the extracellular domain, the transmembrane domain and the cytoplasmic domain. The extracellular domain is capable of specifically binding to a compound, normally called "ligand". Signal transduction appears to occur in a variety of ways upon ligand binding, such

15   as for example by a conformational change in the structure of the receptor, by clustering of two or more identical or related receptor-type molecules.

Many receptors have been identified and the scientific literature has variously divided them into groups, superfamilies, families and/or classes of receptors based on common features such as tissue distribution of the receptors,

20   nucleic acid or amino acid homology of the receptors, mechanisms of signalling by the receptors or the type of ligand that binds to the receptors. A uniform system of classifying or grouping receptors, however, has not been used in the literature.

It is well established that polypeptide hormones elicit their biological effect by

25   binding to receptors expressed on the surface of responsive cells. At least four families of polypeptide hormone receptors can be defined on the basis of similarity in primary sequence, predicted secondary and tertiary structure and biochemical function. These are the haemopoietin/interferon receptor family, the receptor kinase family, the tumour necrosis factor (TNF) / nerve growth

30   factor (NGF) family and the family of G-protein coupled receptors. The haemopoietin/interferon family receptors have no intrinsic enzymatic activity;

2

they can be recognised on the base of their "cytokine receptor homology" (CRH) region in their extracellular domains. This CRH region contains two conserved cystein bridges and a tryptophan - serine - X - tryptophan - serine motif. The defining features of members of the TNF-NGF receptor family are located in the extracellular domain and centre on a domain that contains 6 cysteine residues. The receptor kinase family is characterised by a conserved catalytic kinase domain in the cytoplasmic part of the receptor; the family is subdivided in tyrosine kinase and serine/threonine kinase receptors, on the base of their substrate specificity. While receptors in the haemopoietin, TNF/NGF and kinase families contain a single transmembrane domain, G-protein coupled receptors traverse the membrane several times. With the exception of the G-protein coupled receptors, cytokine driven multimerization of the receptor subunits appears to be the initial event in signal transduction. While homo- or heterodimerization and trimerization are central to the function of haemopoietin / interferon receptors and TNF / NGF receptors, homodimerization appears a preferred way of receptor kinase action.

A special case is that of the receptor-like protein tyrosine phosphatases. All members possess an intracellular part containing one or two homologous protein tyrosine phosphatase domains, a single membrane spanning region and variable extracellular segments with potential ligand binding capacity.

As described above, cytokine-driven interaction between receptor subunits appears to be the initial event for haemopoietin / interferon receptors. The recognition of the ligand starts with one receptor subunit; this subunit is often called a-subunit in case of heteromeric receptors. After this initial event, there is an association of one or more additional receptor molecules, which is essential for the initiation of the signal transduction and, as an additional effect can lead to an increase in affinity of the ligand binding. Receptor clustering leads to activation of the kinase function. The haemopoietin / interferon receptors which, contrary to the tyrosine kinase receptors, do not have an intrinsic kinase activity, are using the help of the associated "Janus kinases" (JAKs) to phosphorylate the tyrosine residues. Subsequent targets

for the JAKs include the JAK molecules themselves, the cytoplasmic part of the receptor and the "Signal Transducers and Activators of Transcription" proteins (STAT). This pathway is called the "JAK / STAT pathway". Additional pathways, such as the Ras - Raf - mitogen activated protein kinase pathway may also be activated.

Examples of the haemopoietin / interferon receptors are, amongst others, the interleukin-5 (IL-5) receptor, the erythropoietin receptor and the interferon receptor family.

The IL-5 receptor is a heteromer consisting of two subunits. The IL-5 receptor α-chain is ligand specific and has a low to intermediate binding affinity. Association with the IL-5 receptor β-chain, that is common with other receptor complexes such as IL-3, results in a high affinity binding complex. Both receptor subunits are required for signalling. Furthermore, signalling requires the cytoplasmic tails of both receptor subunits.

Interferons are classified into two classes. Type I interferons consist of the IFNα group, IFNβ, IFNω and the bovine embryonic form, IFNτ. IFNγ belongs to the second group (type II interferon). The receptor complex of the type I interferons consists of an IFNaR1 subunit and an IFNaR2 subunit. The latter receptor chain exists in three isoforms, resulting from alternative splicing: IFNaR2-1 and IFNaR2-2 are membrane associated but differ in length of the cytoplasmic domain, whereas IFNaR2-3 is a soluble form.

A lot of information about the signal transduction process of these receptors has been obtained by genetic complementation studies, using the 2fTGH cell line (Pellegrini et al., 1989; Darnell et al., 1994) and the 6-16 promoter (Porter et al., 1988). The human 2fTGH cell line is hypoxanthine-guanine phosphoribosyl transferase (HGPRT) deficient, but is containing the xanthine guanine phosphoribosyl transferase (gpt) gene of E. coli, under the control of the type I IFN inducible 6-16 promoter. In cell lines with a functional interferon type I receptor (IFNaR), the 6-16 promoter becomes induced and the gpt gene is transcribed, when IFNα or β is added to the medium. The enzyme produced, xanthine guanine phosphoribosyl transferase (XGPRT) is able to

complement the HGPRT deficiency. This allows a positive or a negative selection. Positive selection (growth of XGPRT producing cells) is carried out on hypoxanthine aminopterine thymidine (HAT) medium, negative selection (dead of XGPRT producing cells) is carried out on DMEM medium with 6-thioguanine (6-TG).

The study of receptor-ligand interactions has revealed a great deal of information about how cells respond to external stimuli. This knowledge has led to the development of several therapeutically important compounds. However, many molecules that control cell growth and development are not yet discovered and there exist so called "orphan receptors", of which the ligand(s) are unknown.

Several methods have been proposed to screen for ligands of orphan receptors. Kinoshita et al.(1995) developed a functional screen in yeast to identify ligands for receptor tyrosine kinases. This method is hampered by the need to have functional expression of the receptor genes in the yeast host. Another yeast system is described in WO/9813513. This system makes use of chimeric Gα proteins in order to couple a mammalian G-protein-coupled receptor to the yeast G-protein intracellular pathway. Also here, the method is restricted to yeast and is thus hampered by the need for functional expression of the mammalian receptor genes in the yeast host. Furthermore, the method is restricted to G-protein-coupled receptors. US 5597693 describes a screening method in mammalian cells that is, however, limited to intracellular receptors of the steroid/thyroid superfamily and can not be used for cytokine receptors. WO 95/21930 describes a screening method for cytokine receptors. In this method, ligands are screened after random mutagenesis of a cell line. Only those ligands can be detected of which the expression can be activated by mutagenesis in the cell type used. Moreover, the isolation of the ligand encoding genes is rather complicated. This is a severe restriction for the usefulness of said screening method. In WO 96/02643, a method is described to screen for ligands of the Denervated Muscle Kinase (DMK) receptor and chimeric variants thereof. However, the

applicability of this method is rather limited and there is no direct, rapid way provided to isolate the genetic material encoding the ligand.

It is the aim of the present invention to provide an easy and powerful screening method in eukaryotic cells, such as insect cells, plant cells or mammalian cells, with the exclusion of yeast cells, for ligands of orphan receptors, preferentially of the multimerizing receptor type, for unknown ligands of known receptors, preferentially multimeric or multimerizing receptors and for the genes encoding these ligands. Hereto, chimeric receptors are constructed, comprising an extracellular domain derived from one protein, preferentially the extracellular domain of a receptor, and a cytoplasmic part derived from another protein which should be a receptor; at least one chimeric receptor is expressed in a eukaryotic host cell which is not a yeast cell. The same eukaryotic host cell comprises a recombinant gene, encoding for a compound of which the expression creates an autocrinic loop, and a reporter system that is activated upon the creation of said autocrinic loop. Preferentially, the compound of which the expression creates an autocrinic loop is a ligand for the chimeric receptor. When this autocrinic loop is closed, the reporter system is switched on, preferentially by the use of a promoter that can be activated as a result of binding said ligand to said chimeric receptor.

All three elements (a first recombinant gene encoding a chimeric receptor, a second recombinant gene encoding said compound, and the reporter system) can be either stably transformed into the eukaryotic cell, or transiently expressed. Transfection methods described in the art can be used to obtain this. Non-limiting examples are methods such as calcium-phosphate transfection (Graham and Van der Eb, 1973), lipofection (Loeffner and Behr, 1993) and retroviral gene transfer (Kitamura et al., 1995). To avoid simultaneous expression of several different cDNA products by one cell, which may result in a decreased expression of the relevant cDNA, the retroviral gene transfer is preferred since, depending on the virus/cell ratio, an average infection of one virus per cell can be obtained.

Moreover, it is clear, for people skilled in the art, that the autocrinic loop can be more complex, and may consist of more than one loop. As a non-limiting example, the recombinant gene may express the ligand of a first (chimeric or non-chimeric) receptor that activates a second gene, which upon activation expresses the ligand of a second receptor, of which the ligand binding results in the induction of the reporter system. It is even not essential that the first and the second receptor are situated within the same cell: it is clear, for people skilled in the art, that one can work with two cell populations, the first one carrying a recombinant gene, expressing a ligand for a receptor for the second cell, which upon binding of the ligand starts to produce the ligand of the chimeric receptor, situated on the first cell. Binding of the latter ligand to the chimeric receptor then results in the expression of the reporter system.

In a first embodiment, the *gpt* selection system can be applied to the screening and/or selection of orphan receptors. Hereto, the extracellular domain of the receptor that is studied is fused to the intracellular domain(s) of IFNaR. The receptor studied may be an orphan receptor or a receptor from which not all the ligands are known. The use of the IFN receptor cytoplasmic tails is sufficient for signal transduction which is required for reporter activation, independent of the function (which may be unknown) of the receptor studied. The ligand is supplied by the creation of an autocrinic loop: cells are transfected by a DNA expression library, where genes, encoding for possible ligands for the orphan receptor, are placed preferentially after a strong, constitutive promoter. It is known, however, to people skilled in the art that other promoters can be used, such as inducible promoters and even an IFN inducible promoter. The production of the cognate ligand induces the transcription of the *gpt* gene, enabling a positive selection in HAT medium. Alternatively, candidate ligands can be added to the medium; survival of the cells in the HAT medium will only be detected when a ligand can activate the orphan receptor.

In a second embodiment, secreted alkaline phosphatase (SEAP) may be used as reporter system. Cells expressing the reporter system can be

identified by measuring the SEAP activity using CSPD (disodium 3-(4-methoxyspirol-1,2-dioxetane-3,2'-(5'-chloro)trichloro {3.3.1.1(3,7)}decan-4-yl)phenyl phosphate) as luminogenic substrate.

The invention is not limited to the use of the cytoplasmic tails of the interferon receptor and the *gpt* selection system, but other receptor systems and/or other inducible promoters and/or other reporter systems and/or other cell lines, known to people skilled in the art may be used. As a non limitative example, PC12 cells (Greene *et al.*, 1976), with a chimeric receptor based on the leptin receptor (Tartaglia *et al.*, 1995) and the inducible promoter from the Pancreatitis associated protein I gene may be used. The reporter system may be based upon the detection of the gene product of an inducible gene, as is the case for Green Fluorescent Protein (GFP) as a non limiting example, or may be based on modification of a protein already present in the cell (proteolytic cleavage, phosphorylation, complex formation...) such as the systems described by Mitra *et al.* (1995), Miyawaki *et al.* (1997) and Romoser *et al.* (1997). Moreover, optimal reporter activation may require a co-stimulus, as is the case for the leptin-forskolin system.

A further aspect of the invention is the screening of compounds that are antagonists of the ligand-receptor binding. Due to the fact that can be screened for the toxicity of *gpt* expression in D-MEM + 6-TG medium, it is possible to set up an antagonistic screening system for compounds that inhibit and/or compete with the binding of the ligand to the chimeric receptor. This can be realized by using the autocrinic loop and adding possible inhibitors to the medium, but it is clear for people skilled in the art that, alternatively, the cell can be transformed with genes encoding candidate inhibitors. Expression of an inhibitor would create an anti-autocrinic loop. In this case, the ligand is produced either by an autocrinic loop, or added to the medium,or the receptor may be mutated and/or genetically modified to a form that constitutively initiates the signalling pathway. Such a screening may be useful in the identification of compounds with potential pharmaceutical applications.

A further aspect of the invention is the screening of compounds in the signalling pathway: a host cell, carrying the chimeric receptor and the gene for its ligand, placed after a promoter, in principle inducible by the chimeric receptor, but where said host cell is missing one or more compounds of the

5 signalling pathway, can be transfected by an expression library in order to complement the signalling pathway. Complemented cells will be detected by the activation of the reporter system. This method could be extremely useful in case a receptor with unknown signalling pathway is placed in the autocrinic loop, before or after the loop that is activating the chimeric receptor.

10 Still another aspect of the invention is the screening of compounds that are involved in the secretory pathway: as the ligand for the chimeric receptor needs to be secreted in order to activate the receptor, both compounds that block the secretion, or compounds that can complement a mutation in the secretory pathway can be screened.

15

Definitions

The following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.

20 <u>multimerizing receptor</u>: every receptor of which the interaction with or binding of the ligand results in the multimerization of receptor components, and/or every protein that can be identified by the people skilled in the art as such a receptor on the base of its amino acid sequence and/or protein structure. Interaction is often the binding to the receptor, but can for instance also be

25 binding to one component of a receptor complex, which subsequently associates with other receptor components to form said receptor complex. Another example is the transient interaction of a ligand with a receptor component leading to a conformational change or allowing a specific enzymatic modification leading to signal transduction.

30

<u>Multimerization</u> can be homo- or heterodimerization, homo- or heterotrimerization, ..., up to complex formation of multiple proteins.

<u>Orphan receptor</u>: every receptor, preferentially a multimerizing receptor, or protein with known receptor components of which no ligand is known that is interacting or binding to this receptor and, as a consequence, initiating or inhibiting the signalling pathway.

<u>Ligand</u>: every compound that can interact with or bind to a receptor, preferentially a multimerizing receptor and that is initiating or inhibiting the signalling pathway by its interaction with or binding to said receptor.

<u>Unknown ligand</u>: every compound that can interact with or bind to a receptor, preferentially a multimerizing receptor and that is initiating or inhibiting the signalling pathway by its interaction with or binding to said receptor, but for which this interaction or binding has not yet been demonstrated.

<u>Compound</u>: means any chemical or biological compound, including simple or complex inorganic or organic molecules, peptides, peptido-mimetics, proteins, antibodies, carbohydrates, phospholipids, nucleic acids or derivatives thereof.

<u>Extracellular domain</u>: means the extracellular domain of a receptor and/or orphan receptor, or a functional fragment thereof characterised by the fact that it still can interact with or bind to a known and/or unknown ligand, or a fragment thereof fused to other amino acid sequences, characterised by the fact that it still can interact with or bind to a known and/or unknown ligand, or a fragment from a non-receptor protein that can interact with or bind to a known and/or unknown ligand.

<u>Bind(ing)</u> means any interaction, be it direct (direct interaction of the compound with the extracellular domain) or indirect (interaction of a

compound with one or more identical and/or non-identical compounds resulting in a complex of which one or more compounds can interact with the extracellular domain), that result in initiating or inhibiting the signalling pathway of the chimeric receptor

Cytoplasmic domain: means the cytoplasmic part of a receptor, or a functional fragment thereof, or a fragment thereof fused to other amino acid sequences, capable of initiating the signalling pathway of said receptor and of inducing a reporter system.

Chimeric receptor: functional receptor comprising an extracellular domain of one receptor and the cytoplasmic domain of another receptor.

Reporter system: every compound of which the synthesis and/or modification and/or complex formation can be detected and/or be used in a screening and/or selection system. The reporter system can be, as a non limiting example, a gene product encoding an enzymatic activity, a coloured compound, a surface compound or a fluorescent compound.

Autocrinic loop: every succession of events by which a cell, carrying a receptor allows the synthesis of a known or unknown compound that, directly or indirectly, induces the activation of said receptor.

Anti-autocrinic loop: every succession of events by which a cell, carrying a receptor allows the synthesis of a known or unknown compound that, directly or indirectly, inhibits the binding of a ligand and/or unknown ligand to said receptor.

Signalling pathway: means every succession of events after the binding of a ligand and/or unknown ligand to an extracellular domain of a natural occurring

11

or chimeric receptor whereby said binding can result in the induction and/or repression of a set of genes.

Selection: means isolation and/or identification of cells in which the reporter
5   system is activated or isolation and/or identification of cells in which the reporter system is not activated.

Examples

10 **I.   CONSTRUCTION OF THE CHIMERIC RECEPTORS**

I.1. Construction of IL-5R/IFNaR chimeric receptors

I.1.1 Construction in the pcDNA3 vector

All polymerase chain reactions (PCR) were performed using the Expand High Fidelity PCR system kit (Boehringer Mannheim). This kit is supplied with an
15 enzyme mix containing thermostable Taq DNA and Pwo DNA polymerases (Barnes et al, 1994). The IL-5Rα extracellular domain sequence (amino acids 1-341, not including the last Trp342 residue) was amplified by PCR using the forward primer MBU-O-37 that contains a Kpn I site and the reverse primer MBU-O-38 (table 1). The sequence encoding the βc extracellular domain
20 (amino acids 1-438, not including the last Val439 residue) was PCR amplified using the forward primer MBU-O-39 which also contains a KpnI site and the reverse primer MBU-O-40. A forward primer MBU-O-41 was used with a reverse primer MBU-O-42, which contains an XhoI site, to amplify the sequence that codes for the IFNaR1 transmembrane (TM) and intracellular
25 (IC) domain (amino acids 436-557, including the last residue of the extracellular domain, Lys436). The forward primer MBU-O-43 was used to amplify the sequence encoding the IFNaR2-1 transmembrane and intracellular domains (amino acids 243-331, including the last residue of the extracellular domain, Lys243) and the IFNaR2-2 TM and IC domains (amino
30 acids 243-515, including the last residue of the extracellular domain, Lys243), respectively in combination with the reverse primers MBU-O-44 and MBU-O-

45, containing an XhoI site. After gel purification, and phosphorylation, six combinations of PCR fragments encoding for the EC on the one hand and for the TM + IC domains on the other hand, were ligated and subsequently used as input DNA in a second PCR reaction:

1) IL-5Rα EC domain fragment + IFNaR1 IC and TM domain fragments, using MBU-O-37 and MBU-O-42 as forward and reverse primers, respectively.

2) IL-5Rα EC domain fragment + IFNaR2-1 IC and TM domain fragments, using MBU-O-37 and MBU-O-44 as forward and reverse primers, respectively.

3) IL-5Rα EC domain fragment + IFNaR2-2 IC and TM domain fragments, using MBU-O-37 and MBU-O-45 as forward and reverse primers, respectively.

4) βc EC domain fragment + IFNaR1 IC and TM domain fragments, using MBU-O-39 and MBU-O-42 as forward and reverse primers, respectively.

5) βc EC domain fragment + IFNaR2-1 IC and TM domain fragments, using MBU-O-39 and MBU-O-44 as forward and reverse primers, respectively.

6) βc EC domain fragment + IFNaR2-2 IC and TM domain fragments, using MBU-O-39 and MBU-O-45 as forward and reverse primers, respectively.

The resultant blunt PCR fragments, coding for the hybrid receptors, were isolated by agarose gel electrophoresis, digested with KpnI - XhoI and ligated into the KpnI-XhoI opened pcDNA3 vector (Invitrogen).

The constructs were checked by DNA sequence analysis and named as follows: pcDNA3-IL-5Rα/IFNaR1, pcDNA3-IL-5Rα/IFNaR2-1, pcDNA3-IL-5Rα /IFNaR2-2, pcDNA3-βc/IFNaR1, pcDNA3-βc/IFNaR2-1 and pcDNA3-β c/IFNaR2-2.

13

Table 1 : oligonucleotides used for construction of chimeric receptors and IL-5
expression vectors.

Number	Specification	forward/reverse	Sequence (5'-3')
MBU-O-37	hIL5Ralpha nt.251-268	Forward	GCTGGTACCATGATCATCGTGGCGCATG
MBU-O-38	hIL5Ralpha nt.1272-1252	Reverse	CTCTCTCAAGGGCTTGTGTTC
MBU-O-39	hbetac nt.29-49	Forward	GCTGGTACCATGGTGCTGGCCCAGGGGCTG
MBU-O-40	hbetac nt.1343-1322	Reverse	CGACTCGGTGTCCCAGGAGCG
MBU-O-41	hIFNaR1 nt.1384-1403	Forward	AAAATTTGGCTTATAGTTGG
MBU-O-42	hIFNaR1 nt.1743-1764	Reverse	CGTCTCGAGGTTCATTTCTGGTCATACAAAG
MBU-O-43	hIFNaR2-1 nt.793-812	Forward	AAAATAGGAGGAATAATTAC
MBU-O-44	hIFNaR2-1 nt.1210-1234	Reverse	CGTCTCGAGACATAATAAAACTTAATCACTGGG
MBU-O-45	hIFNaR2-2 nt.1626-1608	Reverse	CGTCTCGAGATAGTTTTGGAGTCATCTC
MBU-O-278	PacI mutagenesis in IL-5Ralpha/IFNaR2-2	Forward	CACAAGCCCTTGAGAGAGTTAATTAAAATAGGAGGAATAATTACTG
MBU-O-279	PacI mutagenesis in IL-5Ralpha/IFNaR2-2	Reverse	CAGTAATTATTCCTCCTATTTTAATTAACTCTCTCAAGGGCTTGTG
MBU-O-280	PacI mutagenenesis in beta/IFNaR1	Forward	CCTGGGACACCGAGTCGTTAATTAAAATTTGGCTTATAGTTGG
MBU-O-281	PacI mutagenenesis in beta/IFNaR1	Reverse	CCAACTATAAGCCAAATTTTAATTAACGACTCGGTGTCCCAGG
MBU-O-167	hEPO-R primer nt. 105	Forward	CGGGGTACCATGGACCACCTCGGGGCGTCC
MBU-O-308	hEPO-R primer nt. 872	Reverse	CCCTTAATTAAGTCCAGGTCGCTAGGCGTCAG
MBU-O-187	Linker for pMET7-MCS	Sense	TCGACTCAGATCTTCGATATCTCGGTAACCTCACCGGTTCCTCGAGTCT
MBU-O-188	Linker for pMET7-MCS	Antisense	CTAGAGACTCGAGGAACCGGTGAGGTTACCGAGATATCGAAGATCTGAG

I.1.2. Construction in the pSV-SPORT vector and insertion of a PacI site

As an alternative, we also tested the chimeric receptors in the pSV-SPORT expression vector (Life Technologies). This vector contains an SV40 early promoter which is normally weaker as compared to the CMV promoter of the pcDNA3 plasmid.

The genes for the chimeric receptors in pcDNA3-IL-5Rα/IFNaR2-2 and pcDNA3-βc/IFNaR1 were isolated by Asp718 and XhoI digestion and agarose gelelectrophoresis, followed by insertion in the Asp718-SalI opened pSV-SPORT vector. The resulting constructs were verified by sequence analysis and named pSV-SPORT-IL-5Rα/IFNaR2-2 and pSV-SPORT-β c/IFNaR1.

In addition, we inserted a unique PacI restriction site immediately preceding the last amino acid codon of each extracellular domain (Trp341 and Val438 for IL-5Rα and βc, respectively). This enabled us to quickly exchange the IL-5R extracellular domains with the extracellular domains of other receptors. Insertion mutagenesis was performed with the QuickChange site-directed mutagenesis kit (Stratagene), using the oligonucleotides MBU-O-278 (sense) and MBU-O-279 (antisense) for IL-5Rα/IFNaR2-2 and MBU-O-280 (sense) and MBU-O-281 (antisense) for βc/IFNaR1 (table1). As a result, two amino acids (Leu-Ile) were inserted in the membrane-proximal region of the extracellular domain, which did not interfere with receptor functionality. The resulting plasmids were named pSV-SPORT-IL5RαP/IFNaR2-2 and pSV-SPORT-βcP/IFNaR1

I.2. Construction of EPO-R/IFNaR chimeric receptors

RNA was prepared from 5×10^6 TF-1 cells according to the procedure of the RNeasy kit (Qiagen), and dissolved in 50μl water from which 10μl was used for RT-PCR. To these, 2 μl (2μg) of oligodT (12-18 mer; Pharmacia) was added and incubated at 70°C for 10 min. After chilling on ice for 1 min., cDNA was prepared by adding 4μl of RT buffer (10x; Life Sciences), 1 μl

dNTP's (20 mM; Pharmacia), 2µl DTT (0.1M) and 1 µl of MMLV reverse transcriptase (200U; superscript; Life Technologies) so that the total volume was 20 µl. Incubations were successively at RT for 10 min., 42°C for 50 min., 90°C for 5 min. and 0°C for 10 min.. Following this, 0.5 µl RnaseH (2 U; Life

5 Technologies) was added and the mixture was incubated at 37°C for 20 min., followed by chilling on ice. For PCR amplification of the DNA, 5 µl of this mixture was diluted in 17 µl water followed by addition of 1 µl dNTP's (20 mM), 5µl Pfu buffer (10x; Stratagene), and 10 µl (100 ng) of forward and reverse primer for EPO-R (MBU-0-167 and MBU-0-308, respectively, see

10 table 1). The PCR was started at 94°C for 2 min. during which 2 µl Pfu enzyme (5 U; Stratagene) was added (hot start) and followed by 40 cycles with denaturation at 92°C (1 min.), hybridization between 55 till 59°C (1 min.; with an increasing temperature gradient over 4°C during the 40 cycles) and polymerization at 72°C (3 min.; with an increasing time elongation of 0.05

15 min. during every cycle, but only in the last 25 cycles). To finalise, the reaction was hold on 72°C for 12 min. and chilled to 4°C. A band of correct size was isolated from an agarose gel and the DNA was digested with PacI and KpnI and inserted into the PacI-KpnI opened pSV-SPORT-IL-5Rα P/IFNaR2-2 or pSV-SPORT-βcP/IFNaR1 vectors. The resultant vectors were

20 named pSV-SPORT-EPO-R/IFNaR2-2 and EPO-R/IFNaR1, respectively.

II. FUNCTIONALITY OF THE CHIMERIC RECEPTORS

II.1.   IL-5 can activate the 6-16 promoter via IL-5R/IFNaR chimeric receptors.

25 ### II.1.1. Activation of 6-16 *gpt* allows selection of stable colonies.

The following nine combinations of plasmids were transfected in 2fTGH cells:

1. pcDNA3-IL-5Rα/IFNaR1 + pcDNA3-βc/IFNaR1

2. pcDNA3-IL-5Rα/IFNaR1 + pcDNA3-βc/IFNaR2-1

3. pcDNA3-IL-5Rα/IFNaR1 + pcDNA3-βc/IFNaR2-2

30 4. pcDNA3-IL-5Rα/IFNaR2-1 + pcDNA3-βc/IFNaR1

5. pcDNA3-IL-5Rα/IFNaR2-1 + pcDNA3-βc/IFNaR2-1

6. pcDNA3-IL-5Rα/IFNaR2-1 + pcDNA3-βc/IFNaR2-2

7. pcDNA3-IL-5Rα/IFNaR2-2 + pcDNA3-βc/IFNaR1

8. pcDNA3-IL-5Rα/IFNaR2-2 + pcDNA3-βc/IFNaR2-1

9. pcDNA3-IL-5Rα/IFNaR2-2 + pcDNA3-βc/IFNaR2-2

pcDNA3 alone was used for mock transfection.

Transfection was according to the calcium phosphate method (Graham and van der Eb (1973)). For each plasmid, 10 µg DNA was used (20 µg of pcDNA3 for mock transfection). The precipitate was made up in 1 ml and left on the cells overnight (5×10^5 cells/transfection/petridish). The dishes were then washed twice with Dulbecco's PBS (Life Technologies) and cells were left in DMEM (Life Technologies). 48 hours later, DMEM medium + G418 (Calbiochem; 400 µg/ml) was added. 3 days later, cells from every transfection were trypsinized with 5 ml 0.05% trypsine / 0.02% EDTA solution (Life Technologies) and seeded in three wells of a 6-well microtiterplate. The day after, 1) HAT medium (Life Technologies) alone + G418, 2) HAT medium + G418 + 500 U/ml IFNα2b (PeproTech, Inc) or 3) HAT medium + G418 + 1 ng/ml IL-5 (produced in Sf9 cells using published methodologies) was added. 6 days later, small colonies appeared only in the IL-5Rα/IFNaR1 + β c/IFNaR2-2 and IL-5Rα/IFNaR2-2 + βc/IFNaR1 transfections, when the cells were incubated with HAT + G418 + IL-5, indicating that these IL-5R/IFNaR chimeric receptors were functional in that they transmitted the signal to activate the 6-16 promoter. In none of the transfections, growth in HAT medium alone resulted in clear colony formation, while in all transfections, incubation with 500 U/ml IFNα resulted in 50-100 colonies (see table 2).

Table 2

	HAT	HAT + IL-5	HAT + IFNα
IL-5Rα/IFNaR1 + βc/IFNaR1	-	-	+/- 75
IL-5Rα/IFNaR1 + βc/IFNaR2-1	-	-	+/- 50
IL-5Rα/IFNaR1 + βc/IFNaR2-2	-	3	+/- 50
IL-5Rα/IFNaR2-1 + βc/IFNaR1	-	-	+/- 75
IL-5Rα/IFNaR2-1 + βc/IFNaR2-1	-	-	+/- 100
IL-5Rα/IFNaR2-1 + βc/IFNaR2-2	-	-	+/- 100
IL-5Rα/IFNaR2-2 + βc/IFNaR1	-	13	+/- 100
IL-5Rα/IFNaR2-2 + βc/IFNaR2-1	-	-	+/- 100
IL-5Rα/IFNaR2-2 + βc/IFNaR2-2	-	-	+/- 50
mock	-	-	+/- 100

The experiment was repeated twice, with slight modifications in the procedures according to time of adding supplements, changing media and length of incubation times, but similar results were obtained.

5   To isolate single clones, cells stabile transfected with the combinations pcDNA3-IL-5Rα/IFNaR1 + pcDNA3-βc/IFNaR2-2 or pcDNA3-IL-5Rα/IFNaR2-2 + pcDNA3-βc/IFNaR1, were further cultivated for two days in DMEM medium + HT supplement, allowing cells to switch back to normal DMEM medium.   Single cells were isolated by limited dilution in a 96-well
10   microtiterplate and resulting colonies were further grown in DMEM for two weeks for depletion of *gpt*, and stored. 6 colonies of each transfection were further investigated on their IL-5 responsiveness by re-analysing their growth behaviour in HAT medium alone, HAT medium + IL-5, or DMEM medium. Using án inverted microscope, cell survival was visually followed during a two
15   week period and selection of an optimal clone was based on 1) rapid growth in HAT + IL-5 which correlates with rapid growth in DMEM, and 2) pronounced cell death in HAT alone. One clone was selected for each combination: IL-5Rα/IFNaR1 + βc/IFNaR2-2 clone B and IL-5Rα/IFNaR2-2 + βc/IFNaR1 clone C.

20   2ftGH cells that were stabile transfected with the pSV-SPORT IL-5Rα /IFNaR2-2 + pSV-SPORT βc/IFNaR1 vectors were isolated essentially the same way with the exception that selection in G418 medium was omitted. For each plasmid, 10 µg DNA was used (20 µg of pSV-SPORT for mock transfection). The precipitate was made up in 1 ml and left on the cells
25   overnight (5×10^5 cells/transfection/petridish). The dishes were then washed twice with Dulbecco'sPBS and cells were left in DMEM. 24 hours later, cells from every transfection were trypsinized with 5 ml 0.05% trypsine / 0.02% EDTA solution (Life technologies) and seeded in three wells of a 6-well microtiterplate. The day after, 500 U/ml IFNα or 1 ng/ml IL-5 was added or
30   cells were left unstimulated and 24 hours later the medium was removed and replaced by HAT medium with the same stimuli or without stimulus. About 14

days later, small colonies appeared, when the cells were incubated with HAT + IL-5. In none of the transfections, growth in HAT medium alone resulted in clear colony formation, while in all transfections, incubation with 500 U/ml IFN α resulted in a confluent monolayer. Isolation of single colonies was performed essentially the same way as described above. Degree of responsiveness of single colonies to IL-5 was determined by investigating growth in HAT medium supplemented with IL-5, versus cell death in HAT medium alone. Alternatively, cell growth in medium containing 6-thioguanine (6-TG) versus cell death in 6-TG containing medium supplemented with IL-5, was also determined. The survival or death was determined visually during a two-week period, using an inverted microscope A clone with the best response to IL-5 was called 2fTGH IL-5Rα/R2-2 + βc/R1 CloneE.

The cells developed at this stage could already serve as an assay system for the evaluation of exogeneously added ligands.

II.1.2. Construction of p6-16SEAP and development of the 2fTGH-6-16SEAP stabile cell line.

Although formation of stable colonies is a reliable and reproducible assay to investigate chimeric receptor activation, this method suffers from the disadvantage that it is very time-consuming and cannot be used for quantification of receptor functionality. We therefore constructed a plasmid wherein the 6-16 promoter was cloned into the pSEAP vector (Tropix), upstream the reporter gene coding for secreted alkaline phosphatase (SEAP). A HindIII fragment that contained the entire 6-16 promoter was isolated from the plasmid 6-16luci (gift from Sandra Pellegrini, Institut Pasteur, Paris) and inserted in the HindIII-opened pSEAP vector so that the 6-16 promoter was in front of the SEAP gene. The resultant plasmid was named p6-16SEAP.

Stabile 6-16SEAP transfected 2fTGH cell lines were obtained by co-transfection of 20 μg p6-16SEAP with 2 μg pBSpac/deltap (obtained from the Belgian Coordinated Collections of Microorganisms, BCCM) in the 2fTGH cells. The latter plasmid contained a gene for puromycin resistence under

20

control of the constitutive SV40 early promoter. Selection on puromycin was on the basis of methods described in the art. We choose 3 µg puromycin/ml as an optimal concentration for selection of puromycin-resistant 2ftGH cells. Single colonies were isolated by limited dilution in 96-well microtiterplates and investigated on SEAP production after treatment with IFNα or β versus no stimulus. The clones 2fTGH-6-16SEAPclone2 and 2ftGH-6-16SEAPclone5 were selected, based on an optimal stimulation window.

II.1.3. Activation of the 6-16SEAP reporter by IL-5 in transient transfection assays

10 µg of pSV-SPORT-IL-5Rα/IFNaR2-2 and 10µg of pSV-SPORT-βc/IFNaR1 were co-transfected in 2ftGH cells, together with 10µg of the plasmid p6-16SEAP. Transfection was according to the Ca-phosphate procedure (Graham and Van der Eb, 1973). The precipitate was made up in 1 ml and equally dispersed over four wells in a 6-well microtiterplate (165 µl/10^5 cells/well) and left on the cells overnight. Cells were washed twice the next day (2 x with Dulbecco's PBS)and further grown in DMEM medium for 24 hours. The day after, no stimulus, IFNβ (500U/ml; IFNb1a, gift from P. Hochman, Biogen, Cambridge) or IL-5 (1 and 2 ng/ml) was added and the cells were left for another 24 hours. Finally, samples of medium from each well were taken to assay for SEAP activity with the Phospha-Light kit (Tropix), using CSPD as a luminogenic substrate and light production was measured in a Topcount luminometer (Canberra-Packard). Comparison with untreated cells shows a 2.5-fold increase in SEAP activity when the cells were treated with IFNβ as compared to untreated cells, and a 5-or 6-fold increase when cells were stimulated with 1 or 2 ng/ml IL-5, respectively (figure 1).

II.2. Erythropoietin can activate the 6-16 promoter via Epo-R/IFNaR chimeric receptors.

II.2.1. Activation of 6-16 SEAP in transient transfection assays

20 μg of pSV-SPORT-EPO-R/IFNaR2-2 alone, 20 μg of pSV-SPORT-EPO-R/IFNaR1 alone, 10μg of pSV-SPORT-EPO-R/IFNaR1 + 10 μg of pSV-SPORT-EPO-R/IFNaR2-2 or 20 μg of pUC18 alone (mock; Pharmacia) were transfected in 2ftGH-6-16SEAPclone2 cells, using the Ca-phosphate method

5   (Graham and Van der Eb, 1973). The precipitate was made up in 1 ml and left on the cells for six hours (5×10^5 cells/transfection/petridish). The dishes were then washed twice with Dulbecco's PBS and cells were further grown in DMEM. After 24 hours, cells from every transfection were trypsinized with 5 ml 0.05% trypsine / 0.02% EDTA solution (Life Technologies) and seeded in

10   three wells of a 6-well microtiterplate. The next day, no stimulus, IFNα (500U/ml) or erythropoietin (EPO, 0.5 U/ml, R&D systems) was added and the cells were left for another 24 hours. Finally, samples of medium from each well were taken to assay for SEAP activity with the Phospha-Light kit (Tropix), using CSPD as a luminogenic substrate and light production was

15   measured in a Topcount luminometer. Comparison with untreated cells shows a 4-fold increase in SEAP activity when the cells were treated with IFN β or IFNα. There was no induction of SEAP by EPO in the cells transfected with the EPO-R/IFNaR1 chimer alone. However, a 8 to 9-fold induction of SEAP activity by EPO was observed in those cells transfected with the EPO-

20   R/IFNaR1 + EPO-R/IFNaR2-2 constructs or with the EPO-R/IFNaR2-2 construct alone (figure 2), indicating that at least EPO-R/IFNaR2-2 can be activated by EPO and transmits a signal resulting in 6-16 promoter activation.

II.2.2. Development of 2fTGH cells, stabile expressing the EpoR/IFNaR2-

25   **2 chimeras**

2fTGH-6-16SEAP clone5 cells were transfected with 20 μg of pSV-SPORT-EpoR/R2-2 and 2 μg pcDNA1/Neo. A calcium phosphate precipitate was made up in 1 ml according to the method of Graham and Van der Eb (1973), and left on the cells overnight (8×10^5 cells/transfection/petridish). The dishes

30   were then washed twice with PBS and cells were left in DMEM. 48 hours later, DMEM medium + G418 (400 μg/ml) was added and refreshed every 3-4

days for a period up to 14 days. Individual cells were isolated by limited dilution in a 96-well microtiterplate. Degree of responsiveness of single colonies to Epo was determined by investigating growth in HAT medium supplemented with Epo, versus cell death in HAT medium alone.

5   Alternatively, cell growth in medium containing 6-thioguanine (6-TG) versus cell death in 6-TG containing medium supplemented with Epo, was also determined. The survival or death was determined visually during a two-week period, using an inverted microscope. Furthermore, the 2fTGH 6-16SEAP clone 5 cells have the 6-16SEAP construct stabile transfected, allowing fast

10   determination of Epo responsiveness by measurement of SEAP induction. On the basis of these assays, 2fTGH-6-16SEAP EpoR/2-2 clone 4 showed the highest responsiveness for Epo and was selected for further analysis.

III.   ACTIVATION OF THE CHIMERIC RECEPTORS UPON
15   ENDOGENOUSLY PRODUCED LIGAND

III.1. Construction of the vectors pEFBos-hIL-5syn and pMET7-hIL-5syn for constitutive eukaryotic expression of IL-5.

The gene for hIL-5syn was isolated from the pGEM1-hIL-5syn vector (Tavernier et al. 1989) by Sal I digestion and agarose gelelectrophoresis.

20   The fragment was cloned into the Sal I opened pEFBOS vector (gift from Nagata,S., Osaha Bioscience Institute, Japan). As a result, the hIL-5syn gene was cloned downstream the promoter for human elongation factor 1a (HEF1a, Mizushima et al., 1990) and the resultant plasmid was named pEFBos-hIL-5syn. In addition, the Sal I fragment was also cloned into the

25   pMET7MCS vector. This vector was constructed by replacing the DNA encoding the leptin receptor long form (Lrlo) in the plasmid pMET7-Lrlo (gift from L. Tartaglia, Millenium, Cambridge), with the DNA coding for a multicloning site (Sal I-Bgl II-EcoR V-BstE II-Age I-Xho I-Xba I), formed by hybridization of the oligonucleotides MBU-O-187 and MBU-O-188 (table 1).

30   Here, the hIL-5syn gene was cloned downstram the hybrid SRα promoter (Takebe et al. 1988) and the plasmid was named pMET7-hIL-5syn.

III.2. Construction of pMET7-moEpo for constitutive eukaryotic expression of monkey Epo.

The plasmid pMFEpo2 (gift from Dr. C. Laker, Heinrich-Pette-institut), was used as input DNA for PCR amplification of monkey Epo cDNA, using a

5 forward primer (GGAATTCGCCAGGCGCCACCATGGGGGTGCACGAATGTCCTG) that contains a kozak sequence and an EcoR1 site and a reverse primer (GCCTCGAGTCATCTGTCCCCTCTCCTGCAG), containing a XhoI site. The PCR was performed with Pfu polymerase (Stratagene) and the obtained product of ± 600 bp was purified by gel extraction and digested with EcoRI-

10 XhoI. This fragment was inserted into the pMET7mβc/SEAP vector. This plasmid encodes for a chimeric protein (alkaline phosphatase fused to the C-terminal end of the mouse IL-5 beta common (mβc) chain), downstream the SRα promoter. The mβc/SEAP gene was removed by an EcoRI-XhoI digest, allowing ligation of the moEpo fragment into the opened pMET7 vector. The

15 resulting plasmid was named pMET7-moEpo.

III.3. Chimeric receptors allow survival selection upon endogeneously produced ligand.

The plasmids pEFBOS-hIL-5syn or the pUC18 vector (mock) were used for

20 transfection of 2ftGH cells that stabile expressed the IL-5Rα/IFNaR2-2 + β c/IFNaR1 chimeras (2ftGH clone C cells). Transfection was performed overnight according to the Ca-phosphate method (Graham and Van der Eb, 1973). The precipitates were made up in 1 ml and left on the cells overnight (5 x.10^5 cells / transfection / petridish). The next day, cells were washed twice

25 with Dulbecco's PBS. Two days later, cells were incubated on HAT medium alone, after which cell survival was visually followed using an inverted microscope. Three days later, a clear difference in cell confluency between pEFBOS-hIL-5syn and mock transfected cells was visible. Cells, transfected with pEFBOS-hIL-5syn, were trypsinised and a limited dilution was set up in a

30 96-well microtiterplate. Six colonies surviving in HAT medium without IL-5

24

supplementation could be isolated, indicating that these cells produced IL-5 and stimulated the chimeric receptor in an autocrinic fashion.

III.4. Determination of the minimum amount of pEFBOS-hIL-5syn DNA required for generation of an IL-5 autocrinic loop

The occurrence of a relevant cDNA in a pool of irrelevant cDNA within a cDNA library was mimicked by making serial dilutions of the expression vectors containing the gene for hIL-5 in irrelevant vector. A 1:10 dilution series of pEFBOS-hIL-5syn DNA in irrelevant DNA (pcDNA.3) was set up : 1.5 (1/10), 0.15 (1/100), 0.015 (1/1000) and 0.0015 (1/10000) μg of pEFBOS-hIL-5syn DNA were added to 15 μg pcDNA3 DNA and transfected in the IL-5Rα/IFNaR2-2 + βc/IFNaR1 clone C cells. Positive and negative controls were 15 μg of pEFBOS-hIL-5syn and 15 μg of pcDNA3, respectively. Transfection was according to the Ca-phosphate procedure (Graham and Van der Eb, 1973). The precipitates were made up in 1 ml and left on the cells overnight (5×10^5 cells / transfection / petridish). Following washing (2 x with Dulbecco's PBS), DMEM medium was added for 24 hours after which it was changed to HAT medium. Cells were visually followed using an inverted microscope and 15 days after transfection, photographs of representative regions in every petri dish were taken. All of the petri dishes, containing cells transfected with one of the pEFBOS-hIL-5syn dilutions, showed a marked increase in cell number as compared to the negative control (figure 3). Hence, transfection of as little as 1.5 ng pEFBOS-hIL-5syn in 15 μg total DNA ($1:10^4$ dilution) is sufficient to generate an autocrine loop that allows cell survival in HAT medium.

III.5. Determination of the minimum amount of pMET7-hIL-5syn DNA required for generation of an IL-5 autocrinic loop.

A dilution series of pMET7-hIL-5syn DNA in irrelevant DNA (pCDNA3) was set up : 4 ng ($1/10^4$), 400 pg ($1/10^5$), and 40 pg ($1/10^6$) of pMET7-hIL-5syn DNA were added to 40 μg pCDNA3 DNA and transfected in the 2fTGH IL-5R

α/IFNaR2-2 + βc/IFNaR1 CloneE cells (stabile transfected with pSV-SPORT-IL-5Rα/IFNaR2-2 + pSV-SPORT-βc/IFNaR1). As a negative control, 40 μg of pCDNA3 alone was used. 10μg p6-16 SEAP was added to all samples. Every precipitate was prepared in 1 ml according to the Ca-phosphate

5   procedure (Graham and Van der eb, 1973), from which 165 μl (6.8 μg of total DNA) was brought onto 10^5 cells in the well of a 6-well microtiterplate. The precipitate was left on the cells overnight after which cells were washed twice with Dulbecco's PBS. Cells were further grown in DMEM medium. After 24 hours, medium samples were taken from each well and SEAP activity was

10   measured using the Phospha-Light assay (Tropix). Luminescence was measured in a Topcount luminometer. Transfection of the cells with 68 pg pMET7-hIL-5syn in 6.8 μg total DNA ($1/10^5$ dilution of pMET7-hIL-5syn DNA), still resulted in a clear SEAP production, as compared to the negative control, indicating that an autocrine loop was formed (figure 4).

15

III.6. Determination of the minimum amount of pMET7-hIL-5syn DNA required for generation of an IL-5 autocrinic loop by dilution in the pACGGS-EL4cDNA library.

To optimally mimic the occurrence of the cDNA coding for the relevant ligand

20   in a large pool of irrelevant cDNAs, we diluted the pMET7-hIL-5syn plasmid in a cDNA library. This library was made from the mouse EL4 lymphoma cell line and cDNAs were inserted into the vector pACGGS under control of the chicken β-actin promoter. 125 ng ($1/10^2$), 12.5 ng ($1/10^3$), 1.25 ng ($1/10^4$), 125 pg ($1/10^5$), 42 pg ($1/3 \times 10^5$) and 12.5 pg ($1/10^6$) of pMET7-moEpo DNA were

25   added to 9.4 μg pACGGS-EL4cDNA and 3.1 μg p6-16SEAP. As a negative control, we transfected 9.4 μg of pACGGS-EL4cDNA + 3.1 μg of p6-16SEAP. Every precipitate was prepared in 500 μl, according to the Ca-phosphate procedure (Graham and Van der eb, 1973), and 165 μl (± 4μg total DNA) was brought onto 10^5 2fTGH 6-16SEAP EpoR/IFNaR2-2 Clone 4 cells in the well

30   of a 6-well microtiterplate. The precipitate was left on the cells for 6 hours after which cells were washed twice with Dulbecco's PBS. Cells were further

grown in DMEM medium. After 18 hours, medium samples were taken from each well and SEAP activity was measured using the Phospha-Light assay (Tropix). Luminescence was measured in a Topcount luminometer. Transfection of the cells with 400 pg pMET7-hIL-5syn in 4 μg total DNA (1/10⁴

5   dilution), still resulted in a clear SEAP production, as compared to the negative control, indicating that an autocrine loop was formed (figure 5a).

The same dilutions were set up for transfection according to the lipofection method (Loeffner and Behr, 1993). Here, a total of 2 μg was transfected into the cells (4x10⁵ cells/well), in combination with 2.5 μl of DNA carrier

10   (Superfect; Qiagen). Transfection was according to the manufacturers guidelines. The mixture was left on the cells for 2 hours after which the cells were washed. After 18 hours, medium samples were taken from each well and SEAP activity was measured as described above. Also here, transfection of the cells with 200 pg pMET7-hIL-5syn in 2 μg total DNA (1/10⁴ dilution), still

15   resulted in a clear SEAP production, as compared to the negative control, indicating that an autocrine loop was formed (figure 5b).

III.7. Determination of the minimum amount of pMET7-moEpo DNA required for generation of an Epo autocrinic loop by dilution in the
20   **pACGGS-EL4cDNA library.**

To optimally mimic the occurrence of the cDNA coding for the relevant ligand in a large pool of irrelevant cDNAs, we diluted the pMET7-moEpo plasmid in a cDNA library. This library was made from the mouse EL4 lymphoma cell line and cDNAs were inserted into the vector pACGGS under control of the

25   chicken β-actin promoter. 1.25 μg (1/10), 125 ng (1/10²), 12.5 ng (1/10³), 4.2 ng (1/3x10³), 1.25 ng (1/10⁴), 420 pg (1/3x10⁴), 125 pg (1/10⁵), 42 pg (1/3x10⁵) and 12.5 pg (1/10⁶) of pMET7-moEpo DNA were added to 9.4 μg pACGGS-EL4cDNA and 3.1 μg p6-16SEAP and transfected in the 2fTGH 6-16SEAP EpoR/IFNaR2-2 Clone 4 cells. Although in principle not required

30   because of the stable integration of p6-16SEAP in these cells, the addition of p6-16 SEAP to the transfection mixture increased the sensitivity of this assay.

Negative and positive controls were 9.4 µg of pACGGS-EL4cDNA + 3.1 µg of p6-16SEAP, and 9.4 µg pMET7-moEpo + 3.1 µg of p6-16SEAP, respectively. Every precipitate was prepared in 500 µl, according to the Ca-phosphate procedure (Graham and Van der eb, 1973), and 165 µl (about 4 µg total DNA) was brought onto 10^5 cells in the well of a 6-well microtiterplate. The precipitate was left on the cells for 6 hours after which cells were washed twice with Dulbecco's PBS. Cells were further grown in DMEM medium. After 18 hours, medium samples were taken from each well and SEAP activity was measured using the Phospha-Light assay (Tropix). Luminescence was measured in a Topcount luminometer. Transfection of the cells with 400 pg pMET7-hIL-5syn in 4 µg total DNA ($1/10^4$ dilution), still resulted in a clear SEAP production, as compared to the negative control, indicating that an autocrine loop was formed (figure 6).

Short description of the Figures

Figure 1: Transient co-transfection of pSV-SPORT-IL-5Rα/IFNaR2-2, pSV-SPORT-βc/IFNaR1 and p6-16SEAP in 2ftGH cells and analysis of induction of SEAP activity. 24 hours after transfection, cells were left unstimulated or
5   were stimulated with IFNβ (positive control) or IL-5 (1 and 2 ng/ml). Samples from the medium were taken 24 hours after stimulation and SEAP activity was measured using CSPD as a luminogenic substrate (phospha-light kit, Tropix). The amount of light produced was determined in a Topcount luminometer (Packard).

10

Figure 2: Transient transfection of pSV-SPORT-EpoR/IFNaR1 + pSV-SPORT-EpoR/IFNaR2-2, pSV-SPORT-EpoR/IFNaR1 or pSV-SPORT-EpoR/IFNaR2-2 in 2fTGH 6-16SEAP Clone 5 cells. 24 hours after transfection, cells were left unstimulated or were stimulated with IFNβ (1
15   ng/ml; positive control) or Epo (5 ng/ml). Samples from the medium were taken 24 hours after stimulation and SEAP activity was measured using CSPD as luminogenic substrate (phospha-light kit, Tropix). The amount of light was determined in a Topcount luminometer (Packard).

20   Figure 3: Survival of 2fTGH IL-5Rα/IFNaR2-2 + βc/IFNaR1 clone C cells, transfected with dilutions of the vector pEFBOS-hIL-5syn in irrelevant DNA. Formation of an autocrinic loop results in survival of the cells in HAT medium. Fifteen days after transfection, photographs of representative regions in each petridish were taken.

25

Figure 4: Induction of SEAP activity in IL-5Rα/IFNaR2-2 + βc/IFNaR1 clone E, transfected with dilutions of the vector pMET7-hIL-5syn in irrelevant DNA and co-transfected with the p6-16 plasmid. Formation of an autocrinic loop results in activation of the 6-16 promoter followed by secretion of SEAP. Samples
30   from the medium were taken 24 hours after transfection and SEAP activity was measured using CSPD as luminogenic substrate (phospha-light kit,

Tropix). The amount of light produced was determined in a Topcount luminometer (Packard).

Figure 5: A. Induction of SEAP activity in 2fTGH IL-5Rα/IFNaR2-2 + β c/IFNaR1 clone E cells, transfected with dilutions of the vector pMET7-hIL-5syn in an EL4 cDNA library that was expressed in the eukaryotic expression vector pACGGS. All dilutions were co-transfected with the p6-16 plasmid. Negative control was pACGGS-EL4cDNA + p6-16SEAP. Transfection was performed according to the Ca-phosphate method. Formation of an autocrinic loop results in activation of the 6-16 promoter followed by secretion of SEAP. Samples from the medium were taken 24 hours after transfection and SEAP activity was measured using CSPD as luminogenic substrate (phospha-light kit, Tropix). The amount of light produced was determined in a Topcount luminometer (Packard). B. The same conditions were used as above with the exception that transfection was performed according to the lipofection method, using Superfect reagent (Qiagen).

Figure 6: Induction of SEAP activity in 2fTGH 6-16SEAP EpoR/IFNaR2-2 clone 4 cells, transfected with dilutions of the vector pMET7-moEpo in an EL4 cDNA library that was expressed in the eukaryotic expression vector pACGGS. All dilutions were co-transfected with the p6-16 plasmid. Negative control was pACGGS-EL4cDNA + p6-16SEAP. Formation of an autocrinic loop results in activation of the 6-16 promoter followed by secretion of SEAP. Samples from the medium were taken 24 hours after transfection and SEAP activity was measured using CSPD as luminogenic substrate (phospha-light kit, Tropix). The amount of light produced was determined in a Topcount luminometer (Packard).

References

Barnes, W.M. (1994) PCR amplification of up to 35-kb DNA with high fidelity and high yield from lambda bacteriophage templates. Proc. Nat. Acad. Sci. USA, 91, 2216-2220.

5   Darnell, J.E., Kerr, I.M. and Stark, G.R. (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 264, 1415-1421.

Graham, F.L. and Van der Eb (1973) A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology, 52, 456-467.

10   Greene, L.A. and Tischler, A. (1996) Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc. Natl. Acad. Sci. USA, 73, 2424-2428.

Kinoshita, N., Minshull,J. And Kirschner, M.W. (1995): The identification of two novel ligands of the FGF receptor by a yeast screening method and their

15   activity in Xenopus development. Cell, 83, 621-630.

Kitamura, T., Onishi, M., Kinoshita, S., Shibuya, A., Miyajima, A. and Nolan, G. P. (1995) Efficient screening of retroviral cDNA expression libraries. Proc. Natl. Acad. Sci. USA 92, 9146-9150.

Loeffner, J.-P. and Behr, J.-P. (1993) Gene transfer into primary and

20   established mammalian cell lines with lipopolyamine-coated DNA. Meth. Enzymology 217, 599-618.

Mitra, R.D., Silva, C.M. and Youvan, D.C. (1996) Fluorescence resonance energy transfer between blue-emitting and red-shifted excitation derivatives of the green fluorescent protein. Gene, 173, 13-17.

25   Miyawaki, A., et al (1997): Fluorescent indicators for Ca^{2+} based on green fluorescent proteins and calmodulin. Nature, 388,882-887.

Mizushima,S. And Nagata, S. (1990) pEFBOS, a powerful mammalian expression vector. Nucleic acids Res. 18, 5322.

Pellegrini, S., John, J., Shearer, M., Kerr, I.M. and Stark, G.R. (1989) Use of a

30   selectable marker regulated by alpha interferon to obtain mutations in the signaling pathway. Mol. Cell. Biol., 9, 4605-4612.

Pereschini, A., Lynch, J.A. and Rosomer, V.A. (1997) Novel fluorescent indicater proteins for monitoring intracellular Ca2+. Cell Calcium, 22, 209-216.

Porter, A.C.G., Chernajovsky, Y., Dale, T.C., Gilbert, C.S., Stark, G.R. and Kerr, I.M. (1988) Interferon response element of the human gene 6-16. EMBO, 7, 85-92.

Romoser, V.A., Hinkle, P.M. and Persechini, A. (1997) Detection in living cells of Ca2+ dependent changes in the fluorescence emission of an indicator composed of two green fluorescent protein variants linked by a calmodulin-binding sequence. A new class of fluorescent indicators. J. Biol. Chem., 16, 13270-13274.

Takebe, Y., Seiki, M., Fujisawa, J., Hoy, P., Yokota, K., Arai, K., Yoshida, M. And Arai, N. (1988) SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type I long terminal repeat. Mol. Cell. Biol., 8, 466-472.

Tartaglia, L.A., Dembski, M., Weng, X., Deng, N., Culpepper, J., Devos, R., Richards, G.J., Camfield, L.A., Clark, F.T. and Deeds, J.(1994) Identification and expression cloning of a leptin receptor, OB-R. Cell, 83, 1263-1271.

Tavernier, J., Devos, R., Van der Heyden, J., Hauquir, G., Bauden, R., Fache, I., Kawashima, E., Vandekerckhoven J., Contreras, R. and Fiers, W. (1989) Expression of human and murine interleukin-5 in eukaryotic systems. DNA, 8, 491-501.

Claims

1. An eukaryotic cell comprising 1) a first recombinant gene encoding a chimeric receptor 2) a second recombinant gene encoding a compound of which the expression creates an autocrinic or anti-autocrinic loop 3) a reporter system that is activated or inactivated upon the creation of said autocrinic or anti-autocrinic loop.

2. An eukaryotic cell according to claim 1 in which the cell is any cell with the proviso that said cell is not yeast.

3. An eukaryotic cell according to claim 1 or 2 in which the chimeric receptor is a multimeric or multimerising receptor.

4. An eukaryotic cell according to claim 1 - 3 in which said second recombinant gene is placed after a constitutive promoter.

5. An eukaryotic cell according to claim 1 - 4 in which said reporter system is activated as a result of the binding of a ligand to said chimeric receptor.

6. An eukaryotic cell according to any of the preceeding claims in which a cytoplasmic part of the chimeric receptor is a cytoplasmic part of one of the interferon receptor subunits.

7. An eukaryotic cell according to any of the preceeding claims in which the reporter system is E. coli xanthin-guanin phosphoribosyl transferase (gpt).

8. An eukaryotic cell according to claim 6 in which said reporter system is placed under control of the 6-16 promoter

9. An eukaryotic cell according to claim 4 in which said recombinant gene is placed after the SRα or the HEF1a promoter

10. An eukaryotic cell according to any of the preceeding claims in which the cell is a 2fTGH cell.

11. The use of an eukaryotic cell according to any of the preceeding claims for screening for orphan receptors and/or unknown ligands

12. The use of an eukaryotic cell according to claim 1-10 to screen for compounds that interfere with the binding of a ligand with the extracellular part of said chimeric receptor and/or with the signalling pathway of the cytoplasmic part of said chimeric receptor.

13. A method for screening for orphan receptors and/or for unknown ligands comprising a) transformation of an eukaryotic host cell with a gene encoding a chimeric receptor b) transformation of said host cell with a gene encoding a reporter system inducible by the binding of a ligand to said chimeric receptor c) transformation of said host cell with a gene encoding for a ligand of said chimeric receptor d) selection for cells in which the reporter system is activated or inactivated.

14. Orphan receptors and/or unknown ligands, obtainable by the method of claim 13.

15. A method for screening compounds that interfere with the binding of a ligand to a receptor and/or with the signalling pathway of a receptor, comprising a) transformation of an eukaryotic host cell with a gene encoding a chimeric receptor b) transformation of said host cell with a reporter system inducible by the binding of a ligand to said chimeric receptor c) transformation of said host cell with a gene encoding an inhibitor of the binding of said ligand to said chimeric receptor d) transformation of said host cell with a gene encoding a ligand for said chimeric receptor and/or supplying said ligand to the host cell e) selection for cells in which the reporter system is activated or inactivated.

16. A kit, comprising an eukaryotic host cell and one or more transformation vectors, which upon transfection of said cell with said vector or vectors results in an eukaryotic cell according to claim 1-10.

Figure 1

Figure 2

Figure 3

pEFBOS-hIL-5syn:

Amount transfected: | Dilution:

15 ng | 1:1000

1.5 ng | 1:10000

0 ng | 0

pEFBOS-hIL-5syn:

Amount transfected: | Dilution:

15 µg | 1:1

1.5 µg | 1:10

150 ng | 1:100

Figure 4

pMET7-hIL-5syn dilution

Figure 5

A.

B.

Figure 6

SEQUENCE LISTING

<110> VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOL

<120> EUKARYOTIC CELL-BASED GENE INTERACTION CLONING

<130> V9/002-V029

<140>
<141>

<150> 98202528.0
<151> 1998-07-28

<160> 19

<170> PatentIn Ver. 2.1

<210> 1
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: MBU-O-37
      hIL5Ralpha nt.251-268

<400> 1
gctggtacca tgatcatcgt ggcgcatg   28

<210> 2
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: MBU-O-38
      hIL5Ralpha nt.1272-1252

<400> 2
ctctctcaag ggcttgtgtt c   21

<210> 3
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: MBU-O-39
       hbetac nt.29-49

<400> 3
gctggtacca tggtgctggc ccaggggctg   30

<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: MBU-O-40
       hbetac nt.1343-1322

<400> 4
cgactcggtg tcccaggagc g   21

<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: MBU-O-41
       hIFNaRi nt.1384-1403

<400> 5
aaaatttggc ttatagttgg   20

<210> 6
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: MBU-O-42
       hIFNaR1 nt.1743-1764

<400> 6
cgtctcgagg ttcatttctg gtcatacaaa g   31

```
<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: MBU-O-43
      hIFNaR2-1 nt.793-812

<400> 7
aaaataggag gaataattac                                              20


<210> 8
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: MBU-O-44
      hIFNaR2-1 nt.1210-1234

<400> 8
cgtctcgaga cataataaaa cttaatcact ggg                               33


<210> 9
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: MBU-O-45
      hIFNaR2-2 nt.1626-1608

<400> 9
cgtctcgaga tagttttgga gtcatctc                                     28


<210> 10
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: MBU-O-278
      PacI mutagenesis in IL-5Ralpha/IFNaR2-2
```

<400> 10
cacaagccct tgagagagtt aattaaaata ggaggaataa ttactg   46

<210> 11
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: MBU-O-279
      PacI mutagenesis in IL-5Ralpha/IFNaR2-2

<400> 11
cagtaattat tcctcctatt ttaattaact ctctcaaggg cttgtg   46

<210> 12
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: MBU-O-280
      PacI mutagenesis in beta/IFNaR1

<400> 12
cctgggacac cgagtcgtta attaaaattt ggcttatagt tgg   43

<210> 13
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: MBU-O-281
      PacI mutagenesis in beta/IFNaR1

<400> 13
ccaactataa gccaaatttt aattaacgac tcggtgtccc agg   43

<210> 14
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: MBU-O-167
        hEPO-R primer nt.105

<400> 14
cggggtacca tggaccacct cggggcgtcc   30

<210> 15
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: MBU-O-308
        hEPO-R primer nt.872

<400> 15
cccttaatta agtccaggtc gctaggcgtc ag   32

<210> 16
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: MBU-O-187
        Linker for pMET7-MCS

<400> 16
tcgactcaga tcttcgatat ctcggtaacc tcaccggttc ctcgagtct   49

<210> 17
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: MBU-O-188
        Linker for pMET7-MCS

<400> 17
ctagagactc gaggaaccgg tgaggttacc gagatatcga agatctgag   49

<210> 18

```
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: forward primer

<400> 18
ggaattcgcc aggcgccacc atgggggtgc acgaatgtcc tg                      42



<210> 19
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: reverse primer

<400> 19
gcctcgagtc atctgtcccc tctcctgcag                                    30
```

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12   C12N15/62   C12N15/85   C12N5/10   C07K14/715
       C07K14/71   C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 13513 A (CADUS PHARMACEUTICAL CORP) 2 April 1998 (1998-04-02) abstract page 20, line 1 - line 7 page 26, line 1 - line 30 page 65, line 11 -page 71, line 9 examples 8-12	1-5,9-16
Y		6-8
	― -/--	

[X] Further documents are listed in the continuation of box C.   [X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
17 November 1999	03/12/1999

| Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016 | Authorized officer

Galli, I |

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
Y	MUTHUKURMARAN G. ET AL.: "Chimeric Erythropoietin-Interferon gamma receptors reveal differences in functional architecture of intracellular domains for signal transduction" J. BIOL. CHEM., vol. 272, no. 8, 21 February 1997 (1997-02-21), pages 4993-4999, XP002122944 the whole document	6-8
A	PELLEGRINI S ET AL: "USE OF A SELECTABLE MARKER REGULATED BY ALPHA INTERFERON TO OBTAIN MUTATIONS IN THE SIGNALLING PATHWAY" MOLECULAR AND CELLULAR BIOLOGY, vol. 9, no. 11, November 1989 (1989-11), pages 4605-4612, XP000673982 cited in the application the whole document	6-8,10
A	WO 98 16557 A (GEN HOSPITAL CORP) 23 April 1998 (1998-04-23) abstract example 1 claim 4	1-16
A	WO 98 02542 A (UNIV MEDICINE AND DENTISTRY OF) 22 January 1998 (1998-01-22) abstract example 1 page 60, line 22 - line 29 figure 1	1-16
A	WO 96 23814 A (CELL GENESYS INC) 8 August 1996 (1996-08-08) abstract claim 1	1-16

2

INTERNATIONAL SEARCH REPORT

Box I	**Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
   because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.:   14,15
   because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
   See FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II	**Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest
  ☐ The additional search fees were accompanied by the applicant's protest.

  ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

FURTHER INFORMATION CONTINUED FROM   PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 14,15

Claim 14 refers to orphan receptors and ligands susceptible of being
identified with the screening method of the invention, but without giving
a true technical characterization. Moreover, no such compounds are
defined in the application. In consequence, the scope of the said claims
is ambiguous and vague, and their subject-matter is not sufficiently
disclosed and supported (Art. 6 and 6 PCT). No search can be carried out
for such purely speculative claims whose wording is, in fact, a mere
recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of
claims, relating to inventions in respect of which no international
search report has been established need not be the subject of an
international preliminary examination (Rule 66.1(e) PCT). The applicant
is advised that the EPO policy when acting as an International
Preliminary Examining Authority is normally not to carry out a
preliminary examination on matter which has not been searched. This is
the case irrespective of whether or not the claims are amended following
receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9813513	A	02-04-1998	AU	4593097 A	17-04-1998
			EP	0929691 A	21-07-1999
WO 9816557	A	23-04-1998	NONE		
WO 9802542	A	22-01-1998	US	5843697 A	01-12-1998
			AU	3668797 A	09-02-1998
WO 9623814	A	08-08-1996	US	5712149 A	27-01-1998
			AU	4861396 A	21-08-1996
			CA	2221629 A	08-08-1996
			EP	0842194 A	20-05-1998
			US	5686281 A	11-11-1997